Avendus Spark Institutional Equities has initiated coverage on Dr. Agarwal’s Health Care, giving it a ‘buy’ rating and a target price of ₹495. The company is well-positioned in the eye care market, anticipating strong growth driven by acquisitions and surgical revenues.
